Revenue guidance narrowing
Search documents
PTC Therapeutics narrows 2025 revenue guidance to $750M–$800M as Sephience launch accelerates (NASDAQ:PTCT)
Seeking Alpha· 2025-11-05 09:21
Group 1 - The article does not provide any specific content or key points related to a company or industry [1]
